Global Cysticercosis Treatment Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

Cysticercosis Treatment Market Size

• The global cysticercosis treatment market size was valued at USD 455.00 million in 2025 and is expected to reach USD 698.28 million by 2033, at a CAGR of 5.5% during the forecast period
• The market growth is largely driven by the persistent burden of neurocysticercosis in endemic regions, increasing awareness of parasitic infections, and improved diagnosis through advanced imaging and laboratory techniques, leading to earlier and more effective treatment initiation
• Furthermore, rising investments in healthcare infrastructure, expanding access to antiparasitic drugs, and growing initiatives by governments and health organizations to control neglected tropical diseases are strengthening treatment adoption, thereby supporting the overall expansion of the cysticercosis treatment market

Cysticercosis Treatment Market Analysis

• Cysticercosis treatment, encompassing antiparasitic drugs, corticosteroids, antiepileptic medications, and supportive care, is a critical component of managing neurocysticercosis and other parasitic infections, primarily in endemic regions where sanitation challenges and exposure to Taenia solium remain prevalent
• The escalating demand for cysticercosis treatment is primarily driven by the high disease burden in low- and middle-income countries, increasing awareness of parasitic infections, and improved diagnostic capabilities such as CT and MRI scans that enable timely detection and intervention
• North America dominated the cysticercosis treatment market with the largest share of 40.4% in 2025, supported by advanced healthcare infrastructure, higher diagnosis rates, and better access to specialized therapies
• Asia-Pacific is expected to be the fastest growing region during the forecast period due to high endemic prevalence, improving healthcare systems, rising public health initiatives, and expanding access to diagnosis and treatment
• Antiparasitic therapy segment dominated the cysticercosis treatment market with a significant share of 60.8% in 2025, driven by its role as the first-line treatment for eliminating Taenia solium larvae, widespread clinical adoption of drugs such as albendazole and praziquantel, their proven efficacy and affordability, inclusion in standard treatment guidelines, and their broad applicability across mild to severe cases of neurocysticercosis

Report Scope and Cysticercosis Treatment Market Segmentation     

Cysticercosis Treatment Market Trends

“Improved Diagnosis and Integrated Therapeutic Approaches”

• A significant and growing trend in the global cysticercosis treatment market is the increased reliance on advanced diagnostic imaging techniques such as CT scans and MRI, alongside combination therapies involving antiparasitic drugs, corticosteroids, and antiepileptic medications to ensure effective disease management
• For instance, hospitals and neurology centers in endemic regions are increasingly using neuroimaging-based diagnosis followed by albendazole or praziquantel therapy combined with steroids to manage inflammation and seizure risks in neurocysticercosis patients
• Advancements in diagnostic accuracy enable early detection of infections, allowing clinicians to tailor treatment regimens based on lesion load, location, and severity, thereby improving patient outcomes and reducing complications
• The integration of multidisciplinary care approaches, involving neurologists, infectious disease specialists, and radiologists, is facilitating more coordinated and standardized treatment protocols across healthcare systems
• Increasing research and development activities focused on improved antiparasitic formulations and adjunct therapies are further enhancing treatment efficacy and patient compliance
• Growing adoption of telemedicine and digital health platforms is also supporting remote consultation and follow-up care for patients in underserved and rural regions
• This trend toward improved diagnosis and comprehensive treatment strategies is reshaping clinical practices and increasing the effectiveness of cysticercosis management, particularly in endemic and resource-limited settings

Cysticercosis Treatment Market Dynamics

Driver

“Rising Disease Burden and Expanding Public Health Initiatives”

• The increasing prevalence of neurocysticercosis in endemic regions, coupled with growing awareness of parasitic infections, is a major driver for the rising demand for cysticercosis treatment
• For instance, government-led deworming programs and public health campaigns in Latin America and parts of Asia are expanding screening and treatment coverage for parasitic infections, supporting early diagnosis and therapy adoption
• As healthcare access improves in developing regions, more patients are being diagnosed and treated, increasing the utilization of antiparasitic drugs and supportive therapies
• Furthermore, international health organizations and NGOs are actively promoting neglected tropical disease control programs, which is encouraging treatment uptake and strengthening healthcare infrastructure
• Rising investments in healthcare infrastructure and improved availability of essential medicines are further supporting treatment accessibility in emerging economies
• Increasing collaboration between public health authorities and private healthcare providers is enhancing awareness, diagnosis rates, and structured treatment delivery
• The growing emphasis on early intervention, improved diagnostic capabilities, and broader access to essential medicines is collectively driving sustained growth in the cysticercosis treatment market

Restraint/Challenge

“Limited Awareness and Treatment Accessibility Barriers”

• Limited awareness of cysticercosis among populations in endemic rural areas, along with underdiagnosis due to lack of advanced diagnostic infrastructure, poses a significant challenge to market growth
• For instance, in many low-income regions, patients often remain untreated or receive delayed treatment due to inadequate access to imaging technologies and specialized healthcare professionals
• The high cost and limited availability of diagnostic tools such as MRI and CT scans further restrict timely detection and treatment, particularly in resource-constrained healthcare systems
• In addition, variability in treatment guidelines and the need for long-term management of neurological complications can complicate treatment adherence and clinical outcomes
• Shortage of trained healthcare professionals in endemic regions limits proper disease management and follow-up care for affected patients
• Logistical challenges in distributing antiparasitic drugs and ensuring consistent treatment supply chains in remote areas further hinder effective disease control
• Overcoming these challenges through increased awareness programs, improved healthcare accessibility, affordable diagnostics, and strengthened public health infrastructure will be essential for the sustained growth of the cysticercosis treatment market

Cysticercosis Treatment Market Scope

The market is segmented on the basis of drug class, drug type, end-users, and distribution channel.

• By Drug Class

On the basis of drug class, the cysticercosis treatment market is segmented into antiparasitic therapy, corticosteroids, antiepileptic drugs, and surgery. The antiparasitic therapy segment dominated the market with the largest revenue share of 60.8% in 2025, driven by its position as the first-line treatment for eliminating Taenia solium larvae in infected patients. Drugs such as albendazole and praziquantel are widely prescribed due to their proven efficacy, affordability, and inclusion in standard treatment protocols. The segment’s dominance is further supported by its broad applicability across varying disease severities and its use in combination with other supportive therapies. The growing diagnosis of neurocysticercosis cases and increasing access to essential medicines in endemic regions are also contributing to its leading market share.

The antiepileptic drugs segment is expected to witness the fastest growth rate during the forecast period, driven by the high incidence of seizures associated with neurocysticercosis. Many patients require long-term antiepileptic therapy to manage neurological complications, leading to sustained demand. Increasing awareness about seizure management and improved access to neurological care in developing regions are further supporting this segment’s growth. In addition, the rising integration of antiepileptic drugs as part of combination therapy protocols is enhancing their clinical importance. Expanding healthcare infrastructure and better diagnosis of seizure-related complications are expected to accelerate the adoption of this segment.

• By Drug Type

On the basis of drug type, the market is segmented into branded and generic drugs. The generic drugs segment dominated the market with the largest share of 75% in 2025, primarily due to the widespread availability and affordability of generic antiparasitic medications such as albendazole and praziquantel. In low- and middle-income countries, where cysticercosis is most prevalent, cost-effective treatment options are highly preferred, driving the dominance of generics. Governments and healthcare systems also encourage the use of generic drugs to improve accessibility and reduce healthcare expenditure. The presence of multiple manufacturers producing generic formulations further strengthens supply and market penetration.

The branded drugs segment is expected to witness the fastest growth rate during the forecast period, supported by increasing demand for high-quality, regulated, and clinically validated formulations. Branded medications often offer consistent efficacy, improved formulations, and better patient compliance. Rising healthcare awareness, growing preference for trusted pharmaceutical brands, and expansion of private healthcare facilities are contributing to this segment’s growth. In addition, pharmaceutical companies are investing in branding and differentiation strategies to capture premium market segments, particularly in urban and developed healthcare markets.

• By End-Users

On the basis of end-users, the cysticercosis treatment market is segmented into hospitals, homecare, speciality centres, and others. The hospitals segment dominated the market with the largest revenue share of 55% in 2025, as hospitals serve as the primary point of diagnosis and treatment for moderate to severe cases of neurocysticercosis. Hospitals are equipped with advanced imaging technologies, specialized medical professionals, and comprehensive treatment facilities required for managing complications such as seizures and intracranial lesions. The availability of multidisciplinary care and inpatient monitoring further strengthens hospital dominance. Increasing hospital admissions for neurological conditions and growing healthcare infrastructure in emerging economies also contribute to this segment’s leading position.

The speciality centres segment is expected to witness the fastest growth rate during the forecast period, driven by the increasing number of neurology-focused clinics and infectious disease centres. These centres provide targeted and specialized care for parasitic infections, improving treatment outcomes through expert consultation and advanced diagnostics. Rising demand for specialized neurological care, along with growing awareness of disease-specific treatment pathways, is supporting this segment’s expansion. In addition, the development of outpatient-based care models and improved accessibility to speciality services in urban regions are further accelerating growth.

• By Distribution Channel

On the basis of distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment dominated the market with the largest share of 65% in 2025, as most cysticercosis treatments are initiated and dispensed within hospital settings during diagnosis and inpatient care. Hospital pharmacies ensure immediate availability of prescribed medications, particularly for severe cases requiring combination therapy and monitored treatment. The integration of hospital-based procurement systems and direct prescription fulfillment supports this segment’s dominance. The reliance on hospital-based treatment protocols further reinforces the central role of hospital pharmacies in the distribution landscape.

The online pharmacy segment is expected to witness the fastest growth rate during the forecast period, driven by increasing digitalization in healthcare and the growing adoption of e-pharmacy platforms. Online pharmacies offer convenience, doorstep delivery, and improved access to medications, particularly in remote or underserved areas. Rising internet penetration, smartphone usage, and digital health awareness are further supporting this trend. In addition, the expansion of telemedicine services and online prescription fulfillment is enhancing the accessibility of antiparasitic and supportive drugs, making online channels an increasingly important distribution avenue.

Cysticercosis Treatment Market Regional Analysis

• North America dominated the cysticercosis treatment market with the largest share of 40.4% in 2025, supported by advanced healthcare infrastructure, higher diagnosis rates, and better access to specialized therapies
• Healthcare providers in the region benefit from widespread availability of advanced imaging technologies such as CT and MRI, enabling accurate and early detection of cysticercosis cases and timely initiation of treatment
• This strong market position is further supported by higher healthcare expenditure, availability of approved antiparasitic and supportive therapies, and increased awareness among clinicians and patients regarding parasitic infections, establishing the region as a key hub for effective cysticercosis management

U.S. Cysticercosis Treatment Market Insight

The United States cysticercosis treatment market captured a significant revenue share in North America in 2025, supported by strong healthcare infrastructure and advanced diagnostic capabilities. Increased awareness of parasitic infections, coupled with improved screening and neuroimaging technologies, is aiding early detection and treatment. The availability of well-established treatment protocols, including antiparasitic medications and adjunct therapies, further supports market growth. In addition, rising cases linked to immigration patterns and travel, along with strong hospital networks and access to specialized care, are contributing to sustained demand for effective cysticercosis treatment solutions.

Europe Cysticercosis Treatment Market Insight

The Europe cysticercosis treatment market is projected to expand at a steady CAGR throughout the forecast period, driven by increasing awareness of neglected tropical diseases and improvements in healthcare access. Enhanced surveillance systems and government-supported public health initiatives are improving diagnosis rates across the region. The presence of advanced healthcare systems, along with growing migration from endemic regions, is contributing to a higher identified patient population. In addition, collaboration between healthcare institutions and research organizations is fostering better treatment approaches and disease management strategies across both urban and rural settings.

U.K. Cysticercosis Treatment Market Insight

The United Kingdom cysticercosis treatment market is anticipated to grow at a moderate CAGR during the forecast period, driven by improved diagnostic awareness and access to specialized healthcare services. The National Health Service (NHS) plays a crucial role in facilitating timely diagnosis and treatment of parasitic infections. Increased international travel and migration from endemic regions have contributed to a gradual rise in reported cases. Furthermore, the availability of advanced imaging technologies and access to neurologists and infectious disease specialists are supporting effective disease management and improving patient outcomes.

Germany Cysticercosis Treatment Market Insight

The Germany cysticercosis treatment market is expected to expand steadily during the forecast period, supported by a robust healthcare system and strong emphasis on clinical research. Germany’s advanced diagnostic infrastructure enables early identification of neurocysticercosis cases, contributing to timely intervention. The country’s focus on evidence-based medicine and access to specialized care centers enhances treatment efficiency. In addition, increasing awareness among healthcare professionals and the integration of multidisciplinary approaches in treatment are fostering improved disease management and supporting market growth.

Asia-Pacific Cysticercosis Treatment Market Insight

The Asia-Pacific cysticercosis treatment market is poised to grow at the fastest CAGR during the forecast period, driven by a higher disease burden in endemic countries, improving healthcare infrastructure, and rising awareness. Factors such as rapid urbanization, sanitation improvements, and government-led public health initiatives are influencing diagnosis and treatment rates. Increasing access to affordable healthcare services and expanding pharmaceutical availability are also supporting market expansion. The region’s large population base and growing investments in infectious disease control programs further contribute to the rising demand for effective cysticercosis treatment options.

Japan Cysticercosis Treatment Market Insight

The Japan cysticercosis treatment market is witnessing steady growth due to advanced healthcare systems and high standards of medical care. Although the disease prevalence is relatively low, improved diagnostic technologies and routine screening in clinical settings are aiding detection of imported cases. Japan’s strong focus on precision medicine and integrated healthcare solutions supports effective treatment outcomes. In addition, the aging population and increased healthcare utilization are contributing to the demand for specialized neurological and infectious disease management services.

India Cysticercosis Treatment Market Insight

The India cysticercosis treatment market accounted for a significant share in Asia Pacific in 2025, attributed to the higher prevalence of the disease and growing awareness among the population. Factors such as inadequate sanitation in certain regions, dietary habits, and close human-animal interaction contribute to the disease burden. Government initiatives aimed at improving hygiene, sanitation, and public health awareness are playing a key role in disease control. In addition, expanding healthcare infrastructure, increasing access to diagnostic facilities, and the availability of affordable treatment options are driving the growth of the cysticercosis treatment market in the country.

Cysticercosis Treatment Market Share

The Cysticercosis Treatment industry is primarily led by well-established companies, including:

• Merck & Co., Inc. (U.S.)
• Pfizer Inc. (U.S.)
• Sanofi (France)
• GSK plc (India)
• Janssen Pharmaceuticals (Belgium)
• Novartis AG (Switzerland)
• Bayer AG (Germany)
• Teva Pharmaceutical Industries Ltd (Israel)
• Cipla Ltd (India)
• Dr. Reddy’s Laboratories Ltd (India)
• Sun Pharmaceutical Industries Ltd (India)
• Lupin Limited (India)
• Zydus Cadila (India)
• Aurobindo Pharma Ltd (India)
• Sandoz International GmbH (Switzerland)
• Hikma Pharmaceuticals PLC (U.K.)
• Torrent Pharmaceuticals Ltd (India)
• Glenmark Pharmaceuticals Ltd (India)

What are the Recent Developments in Global Cysticercosis Treatment Market?

• In November 2025, the World Health Organization (WHO) and Bayer AG renewed their long-standing partnership aimed at eliminating Taenia solium taeniasis and cysticercosis by enhancing access to key treatments. The collaboration includes continued donation of antiparasitic medicines such as niclosamide and praziquantel to support preventive chemotherapy in endemic regions a key strategy to reduce cysticercosis incidence and prevent neurocysticercosis
• In September 2025, WHO highlighted ambitious targets to expand T. solium control measures across more countries, aiming to increase the number of nations with intensified cysticercosis control from 2 in 2020 to 17 by 2030. The strategy includes combined human and porcine treatment approaches, integrating mass chemotherapy and vaccination efforts to break transmission and reduce disease burden
• In July 2025, researchers published updated findings on serological diagnosis of cysticercosis in humans and pigs, highlighting advances and limitations in blood-based testing that could improve early detection and monitoring of treatment effectiveness. Improved diagnostic tools can lead to more targeted use of antiparasitic therapies such as albendazole and praziquantel, supporting better clinical outcomes and disease control effort
• In May 2025, a cross-sectional study analyzed global trends in cysticercosis-induced epilepsy using data up to 2021, emphasizing that while rates may decline, the absolute number of cases and years lived with disability (YLDs) remain high. The findings underscore the ongoing need for effective treatment strategies, public health interventions, and resource allocation to manage the neurological impacts of cysticercosis globally
• In September 2021, the World Health Organization published evidence-based guidelines on the management of Taenia solium neurocysticercosis, providing clinical recommendations on diagnosis and treatment to improve patient care globally. These guidelines are widely referenced in clinical practice and public health policy for managing cysticercosis

SKU-54106